Micro RNAs (miRNAs) have been shown to circulate in biological fluids and are enclosed in vesicles such as exosomes; they are present in urine and represent a noninvasive methodology to detect biomarkers for diagnostic testing. The low abundance of RNA in urine creates difficulties in its isolation, of which exosomal miRNA is a small fraction, making downstream RNA assays challenging. Here, we investigate methods to maximize exosomal isolation and RNA yield for next-generation deep sequencing. Upon characterizing exosomal proteins and total RNA content in urine, several commercially available kits were tested for their RNA extraction efficiency. We subsequently used the methods with the highest miRNA content to profile baseline miRNA expression using nextgeneration deep sequencing. Comparisons of miRNA profiles were also made with exosomes isolated by differential ultracentrifugation methodology and a commercially available column-based protocol. Overall, miRNAs were found to be significantly enriched and intact in urine-derived exosomes compared with cell-free urine. The presence of other noncoding RNAs such as small nuclear and small nucleolar RNA in the exosomes, in addition to coding sequences related to kidney and bladder conditions, was also detected. Our study extensively characterizes the RNA content of exosomes isolated from urine, providing the potential to identify miRNA biomarkers in human urine.
Micro RNAs (miRNAs) have been shown to circulate in biological fluids and are enclosed in vesicles such as exosomes; they are present in urine and represent a noninvasive methodology to detect biomarkers for diagnostic testing. The low abundance of RNA in urine creates difficulties in its isolation, of which exosomal miRNA is a small fraction, making downstream RNA assays challenging. Here, we investigate methods to maximize exosomal isolation and RNA yield for next-generation deep sequencing. Upon characterizing exosomal proteins and total RNA content in urine, several commercially available kits were tested for their RNA extraction efficiency. We subsequently used the methods with the highest miRNA content to profile baseline miRNA expression using nextgeneration deep sequencing. Comparisons of miRNA profiles were also made with exosomes isolated by differential ultracentrifugation methodology and a commercially available column-based protocol. Overall, miRNAs were found to be significantly enriched and intact in urine-derived exosomes compared with cell-free urine. The presence of other noncoding RNAs such as small nuclear and small nucleolar RNA in the exosomes, in addition to coding sequences related to kidney and bladder conditions, was also detected. Our study extensively characterizes the RNA content of exosomes isolated from urine, providing the potential to identify miRNA biomarkers in human urine. There is increased interest in detecting extracellular micro-RNA (miRNA) from biological fluids to identify biomarkers for disease. miRNAs are a class of small noncoding RNAs (ncRNAs) that are 22-25 nucleotides long, which function to regulate mRNA processing at the transcriptional and posttranscriptional level. They are derived from mRNA hairpins comprising precursor miRNAs that are further processed by endoribonucleases (Dicer and Drosha) to form mature miRNA. The mature miRNA is incorporated into the RNAinduced silencing complex, which binds to complementary sites in the 3 0 untranslated region of their mRNA targets, resulting in the downregulation of gene expression. 1 miRNA originating from specific tissues can be secreted into the extracellular environment, including biological fluids such as urine. 2 Urine is a sterile biological fluid comprising end products generated by protein metabolism that is secreted by the kidneys and can be collected noninvasively and in a simple manner. The majority of urinary miRNA originates from renal and urethral cells, and analysis of these cells can provide a measure of the health of the excretory system. [3] [4] [5] Circulating extracellular miRNA from other tissues within the body can be delivered to renal epithelial cells and released into the urine bound to RNA-binding proteins 6, 7 or packaged into microvesicles such as exosomes. 8 Exosomes are 40-to 100-nm-diameter vesicles released by cells and are formed within multivesicular bodies in the endosomal system. 9 They have been found to be enriched in RNA, including coding RNA and ncRNA species such as miRNA, small nuclear RNA, transfer RNA, ribosomal RNA, and long intergenic RNA. 8, 10 The delivery of large clusters of miRNA in exosomes has the capacity to influence a larger diversity of genes and regulate biological pathways. Profiles of deregulated miRNA secreted into peripheral blood 11 and serum [12] [13] [14] have been generated and suggest that they have diagnostic potential for human disease such as gliobastoma and ovarian cancer. 12, 13 Currently, there are limited methodologies available to efficiently isolate extracellular miRNA from the cell-free component of urine. Recent advances in next-generation sequencing (NGS) technologies have allowed the ability to profile total RNA transcriptomes. The challenges faced using NGS to profile small RNA transcriptomes in urine include isolation of total RNA from urine, of which small RNAs make up a fraction, in addition to the added difficulty of isolating exosomal miRNA.
Here we have systematically characterized exosomal RNA profiles in human urine. We investigated methodologies to obtain high exosomal yields from minimal urine volumes and tested RNA isolation efficiency by using six commercially available extraction kits in order to maximize RNA yields from these RNA-limited samples. These methods were then analyzed using NGS to profile baseline miRNA and other ncRNAs by small RNA deep sequencing. We present a method that is suitable for analyzing circulating miRNA profiles in urine that can be applied to biomarker discovery studies in diseases affecting the kidney and bladder, such as urothelial and renal cell carcinoma.
RESULTS

Isolation and characterization of exosomes isolated from human urine
An optimized differential ultracentrifugation protocol was established to isolate exosomes from urine samples. 15, 16 Tamm-Horsfall protein (THP) polymerization can lower the yield of exosomes by entrapping exosomes within their protein network. 15 Dithiothreitol (DTT) has been used in proteomic studies to depolymerize disulphide bonds of THP, releasing entrapped exosomes that pellet upon re-ultracentrifugation and improving the detection of exosomal proteins. 15, 17 To investigate the requirement of THP depletion from urine for transcriptomic studies, exosome pellets were treated with or without DTT and re-ultracentrifugation ( Figure 1 ).
Exosomes isolated from urine treated with DTT yielded a slight increase of exosomes compared with those treated without DTT, as characterized by western immunoblotting of exosomal markers (Figure 2a ). Cell lysates and exosomes from SH-SY5Y cells were used as a positive control given that the methodology to isolate exosomes from cell line supernatant is well established (Figure 2a) . 18, 19 Furthermore, no significant difference was observed upon comparing the yield of RNA content extracted from exosomes treated with or without DTT (Figure 2b ). To directly visualize the exosomes, transmission electron microscopy (TEM) was used. Vesicles isolated by differential ultracentrifugation were found to have a diameter of 50-100 nm and morphology consistent with previous reports (Figure 2c) . 20, 21 Treatment with DTT significantly reduced the presence of the THP fibril network, as observed in the TEM images (Figure 2c ). We further characterized the sizes of vesicles from cell-free urine and vesicles isolated by ultracentrifugation via the particle-toparticle qNano nanopore-based instrument. The majority of vesicle particles were also found to be between 50 and 100 nm in diameter (Figure 2d ). Given that the treatment with DTT did not significantly improve exosomal yields (Figure 2a ) or affect RNA extraction (Figure 2b ), we considered this treatment to be unnecessary for this transcriptomic study.
Further characterization of exosomes isolated without DTT treatment by western immunoblotting of exosomal markers (Figure 3a ) and non-exosomal markers (nucleoporin, GM130, and Bcl-2) were observed to be highly enriched upon differential ultracentrifugation compared with the various fractions collected during the procedure (whole urine, cell pellet, cell-free urine, and exosome-depleted supernatant, Figure 3a ). In addition, upon analyzing the small RNA species (o200 nt) extracted from individual components of urine, small RNA was found to be enriched in the exosomal pellets (Figure 3b ). Although the cell pellet obtained from whole urine contained significant amounts of small RNA, the majority was found to be degraded RNA (Figure 3c ). Large RNA species (4200 nt), in particular 18S and 28S ribosomal RNA, were not detected in the cell pellet, as determined by Bioanalyser analysis using an RNA Nano chip (RNA integrity number ¼ 0, Figure 3c ), suggesting degradation of the cellular RNA.
Maximization of RNA recovery from urine samples
A systematic comparison between different RNA extraction methods was performed on urine samples uniformly pooled from four healthy control subjects (Supplementary Table S1 online) to obtain sufficient volume for three independent experiments ( Figure 4 ). Six commercial RNA isolation kits were tested using the pooled urine samples. The kits compared in this section were miRNeasy (Qiagen), miRNeasy with RNeasy MinElute Cleanup Kit (Qiagen), mirVana PARIS (Ambion), Trizol LS reagent (Life Technologies) with mirVana (Ambion), miRCURY (Exiqon), and the Urine Exosome RNA Isolation kit (Norgen Biotek). Several modifications of RNA extraction were investigated, including phenol/chloroform extraction and further miRNA enrichment, to determine the best methodology for maximal RNA yield.
With the exception of the Norgen Urine Exosome Isolation kit, the remaining kits involve the isolation of exosomes by differential ultracentrifugation followed by RNA extraction. The majority of these kits use guanidine and phenol extraction methods owing to their combined high efficiency in separating protein and RNA into an interphase and aqueous phase, respectively. One exception is the mirVana kit (Life Technologies), which supplies a phenolfree lysis reagent. Therefore, a minor modification of the mirVana kit was also tested whereby the manufacturer's lysis/ binding reagent was replaced with Trizol LS reagent. In addition, enrichment and separation of miRNA (18-200 nt) from total RNA (4200 nt) was also investigated by using the miRNeasy kit and the RNeasy MinElute Cleanup kit. The Urine Exosome RNA Isolation kit from Norgen Biotek is a centrifugation-independent kit that isolates exosomes by binding urinary exosomes to a proprietary resin and enriching exosomal RNA by lysing the bound exosomes. The RNA is released from the exosomes, which is transferred to a column and contaminants are then removed by washes before the elution of exosomal RNA. We evaluated the Norgen Biotek kit to determine whether a similar result could be achieved for deep sequencing without using the lengthy ultracentrifugation procedure.
RNA extractions were analyzed using a Bioanalyser with the small RNA assays normalized to ng miRNA per ml of urine ( Figure 5 ). The Norgen Biotek kit isolated more than a fourfold increase of small RNA compared with the other isolation kits (Po0.001, Figure 5a ). Among the five kits dependent on the use of differential ultracentrifugation to isolate exosomes, similar yields of small RNA were obtained. Regardless of the kit used, there was high reproducibility and consistency of RNA yield. To confirm an enrichment of intact miRNA in exosomes, RNA extraction was also performed on the cell pellet ( Figure 5b ) and the cell-free component of urine ( Figure 5c ). As expected, there was less consistency and miRNA extracted from the cell pellet, as this contains mostly cellular debris and degraded RNA (Figure 3c ), although most kits were able to extract nucleic acids of less than 200 nt. Overall, a higher yield of total small RNA was extracted from cell-free urine compared with the pellet of isolated exosomes ( Figure 5c ). This is not surprising, as the cell-free urine analyzed in Figure 5c had not been depleted of exosomes. It is important to note that the integrity of the small RNA isolated in cell-free urine cannot be analyzed owing to the absence of ribosomal RNA. Deep sequencing would provide an insight into whether there is an intact population of miRNA fragments extracted from cell-free urine.
In addition to the amount of RNA obtained per sample, the percentage of miRNA recovered from the total RNA extracted was also analyzed by using a Bioanalyser small RNA assay. The highest percentage of miRNA was extracted from exosomes compared with the cell pellet and cell-free urine, suggesting that there is an enrichment of miRNA in exosomes. The most efficient kit that isolated the highest percentage of miRNA was the miRNeasy kit through the separation and enrichment of miRNA from large RNA using the additional RNeasy MinElute column (80%). The second most efficient was the miRNeasy kit (without miRNA enrichment; 70%), followed by the other three kits (approximately 60%). Although miRNA comprised 50% of the small RNA extracted by the Norgen kit, overall the miRNA yield was considerably higher compared with the other methods of extraction (summarized in Table 1 ). Although considerable percentages of miRNA were obtained from the cell pellet and cell-free urine, it cannot be determined whether these fragments between 10 and 40 nt are miRNA or degraded RNA.
On comparing preparation time of the differential ultracentrifugation procedure (4 h), it was found that the Norgen Biotek kit eliminates almost 3 h of preparation time and uses minimal sample volume (5 ml) to isolate exosomal RNA for downstream assays (Table 1) . Unfortunately, protein characterization of the exosomes cannot be performed with the samples extracted from the Norgen Biotek kit. Owing to the high efficiency of the Norgen Biotek kit, we decided to continue the use of this kit to profile exosomal miRNA by deep sequencing and compare the miRNA profiles with exosomes isolated using the differential ultracentrifugation method. 
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Baseline miRNA profiles of exosomal preparations and cell-free urine
Urine samples from three different subjects (Supplementary  Table S1 online) were sequenced using the Ion Torrent Personal Genome Machine (Ion PGM, Life Technologies) sequencing platform. Small RNA libraries were constructed using RNA extracted from exosomes isolated from the ultracentrifugation method and the Norgen Biotek kit. To observe whether there was a selective profile of exosomal miRNA and enrichment by using these methods, deep sequencing was also performed on cell-free urine. Deep sequencing was not performed on cell pellets, as the small RNA libraries constructed were found to contain a high abundance of small complementary DNA (cDNA) inserts, most likely of degraded RNA. miRNA enrichment using the RNeasy MinElute column was not performed, as cDNA library preparation for deep sequencing involves size selection of small RNA, and hence the additional miRNA enrichment step was unnecessary. In addition, the majority of RNA species contained in the exosomes were small RNAs. In all, nine libraries were constructed (n ¼ 3) with identifiable indexes and sequenced on three 318 Ion Torrent chips using the Ion PGM platform. A total of 7,075,206 reads were obtained with an average of 786,134 single-end reads produced per sample. Raw sequences were aligned to the human genome (HG19), and reads were mapped to miRBase V.19 22 (Figure 6 ).
Of these, 535 known miRNAs were identified, which comprised 35% of total reads (Figure 7a , Supplementary Data SD1 online). Upon removing sequences mapped to miRNA, the remaining sequences were mapped to other ncRNAs of the human genome using Ensembl annotations (Homo_sapiens.GRCh37.72). 23 Less than 1% was found to map to other ncRNAs such as small nuclear RNA (0.02%), snoRNA (0.04%), LncRNA (0.02%), and LinRNA (0.17%; Figure 7a ). Coding RNA (3%) mapped to the human genome was also detected in all samples (Supplementary Data SD2 and SD3 online).
Low abundant miRNA sequences containing less than five normalized reads per million were removed. The removal of low abundant miRNA reads eliminates possible artifacts obtained from the normalization of miRNA that are not present in one or more samples. Therefore, miRNA with high read counts are considered abundant and consist of actual raw reads before and after post-processing of NGS data. From our analyses, only 12 miRNAs were abundantly expressed in cell-free urine compared with 66 and 184 miRNAs detected in RNA isolated using the Norgen Biotek kit and by ultracentrifugation of exosomes, respectively (Figure 7b , Supplementary Data SD4 online). For each miRNA identified, the majority of miRNA was present in all three subjects (Figure 8 ).
Upon analyzing common and unique miRNA across all samples, seven miRNAs were found to be common in all samples (Figure 7b) . Surprisingly, there was a low abundance of miRNA in cell-free urine. Although a high yield of small RNA was extracted from cell-free urine (Figure 5c ), it is possible that non-exosomal RNA circulating in cell-free urine is substantially degraded and consequently does not map to miRNA annotations in miRBase. Only two miRNAs (hsa-miR-3648 and hsa-miR-4516) were found to be specifically detected in cell-free urine. A total of 182 miRNAs identified were exosomal specific. By comparing the two exosome preparations, 5 miRNAs were specifically isolated using the Norgen Biotek kit (Table 2 ) and 51 miRNAs were detected in both samples.
However, the majority of miRNAs (184) identified in this study were extracted from exosomes isolated by using the ultracentrifuge, comprising 126 specific miRNAs (Figure 7b ). The 10 most abundant miRNAs detected in the three samples (n ¼ 3) were pooled and presented in Table 3 . Those that are common across the three samples are outlined in bold. This table illustrates that the Norgen Biotek kit isolates miRNA that can be found both in cell-free and ultracentrifuge exosomes.
DISCUSSION
The advantages of using urine in clinical tests are that it is collected noninvasively, and the procedure is relatively fast and cost-efficient compared with other clinical samples such as blood and cerebrospinal fluid. A number of recent studies have pooled patient samples in order to perform microarray or quantitative PCR analysis, as it is difficult to obtain enough RNA to successfully construct cDNA libraries for high-throughput deep sequencing. 24, 25 Most studies use the urine cellular sediment obtained after low-speed centrifugation for miRNA analysis. 4, [26] [27] [28] [29] [30] However, we detected a large proportion of low-quality and degraded RNA in the cell pellets of urine. This is not surprising, as there is a high presence of RNase activity in the kidneys, bladder, and urinary tract to maintain sterility and protect the excretory system from microbial infections. 31, 32 False-positive reads can be uncovered upon analyzing deep sequencing data whereby degraded RNA sequences align to the human genome and map to small RNA annotations.
Fewer studies have used cell-free urine or exosomes to isolate miRNAs as we have done in this study. 24, 29, 33 A possible reason could be because of the technical difficulties of handling large liquid volumes during RNA extraction. However, once separated, exosomes isolated from cell-free urine may contain genetic material originating from other tissues from the body apart from the excretory system. Irrespective of the RNA extraction method, quantification of miRNA yield by small RNA analysis demonstrated that intact miRNAs are enriched in exosomes compared with the cell pellet and cell-free component of urine. The abundance of miRNA in exosomes further supports the function of the protective membrane enclosure of exosomes that allows the shuttling of genetic material in biological fluids otherwise, degraded by RNase activity. The notion that urinary exosomes contain a stable source of miRNA makes urine an appealing biological specimen to discover biomarkers. Here, we have successfully characterized exosomes isolated by differential ultracentrifugation and optimized conditions to increase exosomal yield for transcriptome studies. The depletion of THP was found to be unwarranted in the isolation procedure, as exosomal yield was sufficient from 20 ml of urine without DTT treatment. To extract exosomal RNA, the most efficient commercially available kits to maximize RNA extraction from exosomes were the miRNeasy kit (Qiagen) and mirVana Kit (Ambion).
To gain a thorough insight into exosome-specific miRNA, comparisons of exosomal profiles were analyzed against miRNA profiles from cell-free urine. Unlike miRNA profiles sequenced from plasma, cell-free urine does not contain a high abundance of miRNA. From 2.5 ml of cell-free urine, only 12 miRNAs were abundantly expressed. In contrast, 1 ml of plasma or serum can contain more than 500 miRNAs. 34, 35 The low abundance of miRNA-detected cell-free urine further supports the presence of high RNase activity in the bladder compared with serum. 36 The volume (20 ml) of urine required to isolate a sufficient quantity of exosomes was far greater than the volume of cell-free urine (2.5 ml) required to isolate circulating miRNA. However, from the small pellet of exosomes isolated by using the ultracentrifuge, 184 exosomal miRNAs were detected. Only 7 miRNAs of the 184 were common to the cell-free urine, indicating the selective packaging of miRNA or a result reflective of the lack of miRNA detected in cell-free urine. Exosomal-associated miRNAs were detected, such as hsa-Let-7b, hsa-miR-29b, hsa-miR-200c, and hsa-miR-21. 10, 37, 38 Microarray analysis of urine exosomes detected 194 miRNAs in 11 samples of pooled urine, and it was performed in a study investigating miRNA expression response to salt intake and blood pressure. 25 This demonstrates the power of unbiased high-throughput deep sequencing, which was able to detect 184 miRNAs from only three samples using the procedures outlined in this study.
We utilized a commercial exosome to RNA isolation kit by Norgen Biotek to investigate whether the protocol would be suitable for NGS. The advantage of the Norgen Biotek kit is that it does not require an ultracentrifuge and is suitable for clinical laboratories. Interestingly, the Norgen Biotek kit isolated almost four times the amount of miRNA compared with ultracentrifugation methods. Upon further analysis, a different miRNA profile was obtained from the Norgen Biotek kit compared with that profiled from characterized exosomes isolated by ultracentrifugation. The majority of miRNAs (51) extracted using the Norgen Biotek kit were also detected in exosomes isolated by the ultracentrifugation method. However, 4 of the 10 most abundant miRNAs (hsamiR-451a, hsa-miR-125a-5p, hsa-miR-191-5p, and hsa-miR-223-3p) were also found in the cell-free urine, indicating some potential non-exosomal miRNA contamination with the Norgen kit procedure. Nonetheless, applications that require a time-efficient protocol that delivers a consistent yield of highly abundant intact miRNA from urine would value the Norgen Biotek kit to be suitable for downstream assays such as deep sequencing and quantitative PCR.
In addition to miRNA, less than 1% of reads were mapped to ncRNA annotations. Most of the reads (61%) mapped to regions in between genes. Coding RNA was also detected (3%). The most abundant coding RNA detected in cell-free urine was thrombomodulin (NM_000361), a protein cofactor expressed on endothelial cell surfaces and detected in the glomerulus of the kidneys. 39 In exosomes isolated by ultracentrifugation, CTC1 (NM_025099) was frequently expressed. CTC1 is a CTS telomere maintenance complex component 1 that protects telomeres from degradation. The elevation of telomere cofactors has been detected in bladder cancer. 40 Finally, STMN1 (NM_203401) was frequently expressed in exosomes isolated using the Norgen Biotek kit, followed by THBP. STMN1 encodes a ubiquitous cytosolic phosphoprotein proposed to function as an intracellular feedback signal relating to the cellular environment. An increase of the STMN1 protein has been associated with urothelial carcinoma of the bladder. 41 Other ncRNAs (61%) Cell free hsa-miR-16-5p hsa-miR-301a-3p hsa-miR-664a-3p
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hsa-miR-18a-5p Figure 8 | The presence of the highly abundant micro RNAs (miRNAs) identified across each subject. Heat maps demonstrating the presence or absence of each miRNA identified in cell-free or exosomal preparations across each subject. NG, Norgen Biotek Urine Exosomal RNA kit; UC, ultracentrifuge.
were found to be mapped in between gene regions. The high percentage of reads mapped in between introns may be because of the biological nature of urine and function of the kidneys to excrete waste. Deep sequencing of exosomes isolated from other biological fluids such as plasma and saliva typically do not contain a high percentage of reads mapped in between genes, as seen in our laboratory and other studies. 42, 43 In addition, a small percentage of these reads were those mapped to transcripts resulting from manual curation of genome annotations with unknown functions. The methods described here can be used to identify miRNA biomarkers in a number of diseases such as cancer and used to monitor patients in therapeutic drug trials.
MATERIALS AND METHODS Exosome isolation
Morning urine was collected from four healthy volunteers with informed consent and stored at À 80 1C until use. Ethical approval was obtained from the University of Melbourne Health Sciences Human Ethics Sub-committee (#1136882). Upon thawing on ice, urine was vortexed for 90 s. Urine samples (20 ml) were centrifuged at 500 g for 15 min to pellet the cells and cellular debris. The cell-free supernatant was transferred into Ti70 centrifuge tubes and centrifuged at 17,000 g for 45 min at 4 1C (70Ti rotor, Beckman Coulter, Gladesville, NSW, Australia) to remove large membrane vesicles. The supernatant was transferred to a new tube and centrifuged at 200,000 g for 65 min at 4 1C to pellet exosomes, which were resuspended in 30 ml of phosphate-buffered saline (PBS). Where indicated, exosome pellets were resuspended in 200 mg/ml DTT and incubated at 37 1C for 10 min. After incubation with DTT, exosomes were transferred to an ultracentrifuge tube and resuspended with cold 0.2-mm-filtered PBS buffer. The sample was centrifuged at 200,000 g for 65 min to pellet the DTT-treated exosomes.
Western immunoblotting
The cell pellet, cell-free and isolated exosomes of urine were lysed in lysis buffer (50 mmol/l Tris pH 7.4, 150 mmol/l sodium chloride, 1% Triton X-100, 1% sodium-deoxycholic acid, and complete ULTRA protease inhibitors (Roche, Hawthorn, VIC, Australia)) on ice for 1 h and then centrifuged at 17,000 g for 20 min. The supernatant was collected and transferred to a new tube. Samples (20 mg) were diluted in SDS loading buffer resolved on 4-12% Bis-Tris NUPAGE SDS-PAGE gels (Life Technologies, Mulgrave, VIC, Australia) and transferred onto Immobilon-P PVDF membrane (Millipore, Darmstadt, Germany). The membranes were blocked with 5% skim milk buffer in PBS containing 0.05% tween, followed by incubation with primary antibodies to anti-Tsg101, anti-flotillin, anti-CD63, anti-Bcl2, anti-nucleoporin, and anti-GM130. Immunoreactive bands were visualized by using the enhanced Chemiluminescence kit (Amersham Biosciences, Rydalmere, NSW, Australia) followed by exposure to Hyperfilm (Amersham Biosciences) and then developed by the Exomat automated developing system.
Electron microscopy
Exosomes were fixed with 2% glutaraldehyde/PBS for 30 min at room temperature. A volume of 6 ml was applied to a glowdischarged 200-mesh Cu grid coated with carbon-Formvar film (ProSciTech, Kirwan, QLD, Australia) and allowed to absorb for 5 min. Grids were washed twice with MilliQ water and contrasted with 1.5% uranyl acetate. TEM was performed on a Tecnai G 2 F30 (FEI, Eindhoven, NL) TEM operating at 300 kV across Â15,000 to Â36,000 magnification. Electron micrographs were captured with a Gatan UltraScan s 1000 2 kÂ2 k CCD camera (Gatan, Pleasanton, CA).
Size distribution analysis
Scanning ion occlusion sensing analysis was performed using the qNano system (Izon, Christchurch, New Zealand); by applying a voltage and pressure, single particles are passed through a polyurethane nanopore, resulting in a change in ionic current, termed a 'blockade event.' Exosomes were resuspended in PBS with 0.025% Tween-20 to reduce aggregation. Before measurement, exosomes and cell-free urine were passed through a 0.22-mm filter. Blockade events were calibrated against particles of a known size measured under identical settings.
RNA extractions
Six commercially available kits were compared for total RNA extraction from the cell pellet, cell-free pellets, and exosome pellets from urine: miRNeasy (Qiagen, Limburg, NL), miRNeasy with RNeasy MinElute Cleanup Kit (Qiagen), mirVana PARIS (Ambion, Mulgrave, VIC, Australia), Trizol LS reagent (Life Technologies) with mirVana (Ambion), miRCURY (Exiqon, Vedbaek, Denmark), and Urine Exosome RNA Isolation kit (Norgen Biotek, Thorold, ON, Canada). The manufacturers' protocol was followed and total RNA extractions (418 nt) including the recovery of small RNA were performed on the same pool of urine samples in triplicate for each kit. RNA extractions were eluted in 100 ml and stored at À 80 1C until use. The quantity and quality of the RNA extractions were determined by the Agilent Bioanalyser 2100 with a small RNA Chip for exosomal and cell-free miRNA, and an RNA Nano Chip for cellular RNA of the urine (Agilent Technologies, Mulgrave, VIC, Australia). miRNA and small RNA yields were normalized to ng RNA per ml of urine.
Small RNA library construction and sequencing Deep sequencing was performed on three individual urine samples, which were processed separately for exosomal and cell-free RNA isolations (n ¼ 3). For each library, 1 ng of RNA was ligated to adaptors containing a unique index bar code (Ion Xpress RNA-Seq Barcode 1-16 Kit; Life Technologies). RNA samples were reverse transcribed to cDNA using adaptor-specific primers. Using the Magnetic Bead Purification Module (Life Technologies), cDNA samples were size-selected from 94 to 130 nt (the length of the miRNA insert including the 3 0 and 5 0 adaptors). PCR amplification was then performed, followed by a library clean-up using nucleic acid beads (Life Technologies) and eluted in 10 ml of nuclease-free 
Sequencing data analysis
Following sequencing on the Ion Torrent PGM, preprocessing of reads, removal of adaptors, and bar codes were performed by the Torrent Suite (Life Technologies). Sequences were analyzed for quality control (FASTQC) and aligned to the Human genome (HG19) using the Torrent Suite. Output files (*.bam) were uploaded and analyzed using the Partek Genomic Suite software (Partek, Helios, Singapore). Sequences aligned to the human genome were mapped to miRBase_v. 19 (ref. 22) and Emsembl release 17 (ref. 23) . Reads were normalized to reads per million calculated as follows: Number of sequenced reads/total readsÂ1,000,000. miRNA identified in this study were uploaded to Vesiclepedia (microvesicles.org) 4 
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